World Health Organization Sounds Alert Over Acute Scarcity of Obesity Jabs

Less than a tenth of people that would benefit from GLP-1 drugs including Wegovy have access to them, states the WHO as it releases its first advice on the medications.

With in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for broader and more equitable access to this class of drugs.

Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.

"Our new guidance acknowledges that obesity is a long-term condition that can be treated with comprehensive and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and logistical bottlenecks are major hurdles to widespread access to the jabs that can aid individuals in losing substantial weight, explains the body.

Skinny Jab Scarcity

Even in the present best projected outlook, the supply of such drugs could only cover about 100 million people – less than 10% of those who need them, according to the health organization.

The recommendation urges governments and firms to widen access, through measures such as patent sharing.

The intellectual property rights on a key compound – the primary component of a leading brand – is set to lapse in multiple nations in 2026.

The Way Obesity Injections Work

These medications replicate a natural hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so users eat less.

People typically see weight reduction in the initial weeks of beginning the weekly injections.

Research suggests users may see weight return a year later of stopping the medication, as their typical appetite return.

To be carrying excess weight increases your likelihood for experiencing medical conditions, including type 2 diabetes, heart disease, stroke, and some cancers.

Obesity impacts individuals in countries worldwide and was associated with millions of fatalities worldwide in 2024, as per the WHO.